(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Illustrations Gained from a Crosscountry Excursion - 2Share your pick for the miniature headphones that you generally suggest!
- 3Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go
- 4Israeli military says it hit dozens of military facilities in Tehran
- 5This Underrated Italian City Boasts Indulgent Food & Captivating Views For A Romantic Escape
- An Aide On Upgrading Your FICO rating
- Australia’s post-Bondi crackdown accused of targeting pro-Palestinian voices
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
- Artemis II crew cleared to depart Earth orbit, head for moon
- RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- No more attempts to free whale stranded off Germany, officials say
- Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
